drugset / Trial / NCT03221400

PEN-866 in Patients With Advanced Solid Malignancies

NCT03221400

Phase 1/2 Unknown 340 enrolled Tarveda Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

Timeline

Start
2017-08-29
Primary completion
2023-01
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PEN-866 Other / unclassified Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Niraparib Small molecule
Background fluorouracil Small molecule 2400 mg/m2 Intravenous